Literature DB >> 10480504

Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania: a prospective study.

V Dargis1, O Pantelejeva, A Jonushaite, L Vileikyte, A J Boulton.   

Abstract

OBJECTIVE: To assess the ability of a multidisciplinary approach to diabetic foot care to reduce the incidence of recurrent ulceration and amputations compared with standard care in a 2-year prospective study. RESEARCH DESIGN AND METHODS: A total of 145 patients with a past history of neuropathic foot ulcers but no evidence of peripheral vascular disease entered the study. Subjects were screened for their neuropathic and vascular status at baseline, and all received identical foot care education. The intervention group (n = 56) was followed by the multidisciplinary team of physicians, nurses, and podiatrists with regular podiatry and reeducation every 3 months and the provision of specialty footwear as required. The standard treatment group was followed in local clinics on a trimonthly basis and received identical screening and education at baseline.
RESULTS: There were no significant differences at baseline in age (intervention 59.2+/-13.4, standard treatment 58.5+/-11.5 years), duration of diabetes (14.0+/-7.1 vs. 15.6+/-7.8 years), or neuropathic status (vibration perception threshold [VPT]: 31.1+/-12.1 vs. 33.9+/-11.3 V, neuropathy disability score [NDS]: 8.1+/-1.4 vs. 7.9+/-1.7). All patients had an ankle brachial pressure index (ABPI) of >0.9 and at least one palpable foot pulse. Significantly fewer recurrent ulcers were seen in the intervention group than in the standard treatment group during the 2-year period (30.4 vs. 58.4%, P < 0.001).
CONCLUSIONS: This prospective study has demonstrated the effectiveness of a multidisciplinary approach to diabetic foot care together with the provision of specialty footwear in the long-term management of high-risk patients with a history of neuropathic foot ulcers.

Entities:  

Mesh:

Year:  1999        PMID: 10480504     DOI: 10.2337/diacare.22.9.1428

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  30 in total

Review 1.  Treatments for diabetic neuropathy.

Authors:  A J Boulton
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

Review 2.  Risk factors for diabetic neuropathy and foot ulceration.

Authors:  A Adler
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

3.  Temperature monitoring to assess, predict, and prevent diabetic foot complications.

Authors:  Lawrence A Lavery; David G Armstrong
Journal:  Curr Diab Rep       Date:  2007-12       Impact factor: 4.810

Review 4.  Diagnostics and treatment of the diabetic foot.

Authors:  Jan Apelqvist
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

Review 5.  A review of the surgical management of heel pressure ulcers in the 21st century.

Authors:  David C Bosanquet; Ann M Wright; Richard D White; Ian M Williams
Journal:  Int Wound J       Date:  2015-02-16       Impact factor: 3.315

6.  A Critical Evaluation of Existing Diabetic Foot Screening Guidelines.

Authors:  Cynthia Formosa; Alfred Gatt; Nachiappan Chockalingam
Journal:  Rev Diabet Stud       Date:  2016-08-10

Review 7.  Diabetic foot screening: why is it neglected?

Authors:  Ma'en Zaid Abu-Qamar
Journal:  Int Wound J       Date:  2006-09       Impact factor: 3.315

Review 8.  Reducing the incidence of foot ulceration and amputation in diabetes.

Authors:  Cynthia L Bartus; David J Margolis
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

9.  Illustration of Cost Saving Implications of Lower Extremity Nerve Decompression to Prevent Recurrence of Diabetic Foot Ulceration.

Authors:  Timothy M Rankin; John D Miller; Angelika C Gruessner; D Scott Nickerson
Journal:  J Diabetes Sci Technol       Date:  2015-06-08

10.  The international consensus and practical guidelines on the management and prevention of the diabetic foot.

Authors:  Nicolaas C Schaper; Jan Apelqvist; Karel Bakker
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.